FDA Backs CBD for Rare Condition of Neonatal Hypoxic-Ischemic Encephalopathy (NHIE)

| in News |

We are excited to see that the Food and Drug Administration (FDA) is bringing common sense to the research and application of Cannabidiol (CBD) for Neonatal Hypoxic-Ischemic Encephalopathy, or NHIE.  

GW Pharmaceuticals is working on a clinical development program to be able to research this medical condition as well as find out if there is an opportunity to treat such with CBD.

According to BusinessWeekly,

"A drug development program with Fast Track designation is afforded greater access to the FDA for the purpose of expediting the drug's development, review and potential approval to get important new drugs to the patient earlier." 

This is helpful for both researching the potential of CBD with the condition of NHIE as well as providing faster access to patients across the country.  At That's Natural we advocate for Food and Medicine Freedom, and are happy to see more common sense coming to agriculture and medicine policy for the non-psychoactive use of cannabis, through Cannabidiol (CBD).